Since then, various PD-1/PD-L1 inhibitors have been approved for the treatment of advanced head and neck malignancies (40), melanoma (41), Hodgkin’s lymphoma (42), non-small cell lung cancer (43), and other tumors, all of which have shown significant clinical benefits. The gene discussed is CD274; the disease is non-small cell lung carcinoma.